BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 11255561)

  • 1. Novel agents to modulate oestrogen action.
    Dardes RC; Jordan VC
    Br Med Bull; 2000; 56(3):773-86. PubMed ID: 11255561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
    Jordan VC; Gapstur S; Morrow M
    J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Specific estrogen receptor modulators (SERMs)].
    Trémollières F; Lopes P
    Presse Med; 2002 Sep; 31(28):1323-8. PubMed ID: 12355995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective estrogen receptor modulators: a look ahead.
    Mitlak BH; Cohen FJ
    Drugs; 1999 May; 57(5):653-63. PubMed ID: 10353293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Selective estrogen-receptor modulators (SERM's) in postmenopausal women].
    Hart W; Netelenbos JC
    Ned Tijdschr Geneeskd; 1999 Aug; 143(35):1771-6. PubMed ID: 10494328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacological review of selective oestrogen receptor modulators.
    Goldstein SR; Siddhanti S; Ciaccia AV; Plouffe L
    Hum Reprod Update; 2000; 6(3):212-24. PubMed ID: 10874566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skeletal effects of selective oestrogen receptor modulators (SERMs).
    Díez JL
    Hum Reprod Update; 2000; 6(3):255-8. PubMed ID: 10874570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene.
    Ko SS; Jordan VC
    Expert Opin Pharmacother; 2011 Mar; 12(4):657-74. PubMed ID: 21294695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer.
    Dhingra K
    Cancer Invest; 2001; 19(6):649-59. PubMed ID: 11486708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SERMs for the treatment and prevention of breast cancer.
    Swaby RF; Sharma CG; Jordan VC
    Rev Endocr Metab Disord; 2007 Sep; 8(3):229-39. PubMed ID: 17440819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of SERMs for treatment in postmenopausal women.
    Pinkerton JV; Thomas S
    J Steroid Biochem Mol Biol; 2014 Jul; 142():142-54. PubMed ID: 24373794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond raloxifene for the prevention of osteoporosis and breast cancer.
    Jordan VC
    Br J Pharmacol; 2007 Jan; 150(1):3-4. PubMed ID: 17115068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoprevention of breast cancer: implications for postmenopausal women.
    Fabian CJ; Kimler BF
    Drugs Aging; 2002; 19(1):43-78. PubMed ID: 11929326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular effects of raloxifene hydrochloride.
    Saitta A; Morabito N; Frisina N; Cucinotte D; Corrado F; D'Anna R; Altavilla D; Squadrito G; Minutoli L; Arcoraci V; Cancellieri F; Squadrito F
    Cardiovasc Drug Rev; 2001; 19(1):57-74. PubMed ID: 11314601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications.
    Vogelvang TE; van der Mooren MJ; Mijatovic V
    Treat Endocrinol; 2004; 3(2):105-15. PubMed ID: 15743106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The selective estrogen receptor modulators in breast cancer prevention.
    Li F; Dou J; Wei L; Li S; Liu J
    Cancer Chemother Pharmacol; 2016 May; 77(5):895-903. PubMed ID: 26787504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoprevention with antiestrogens: the beginning of the end for breast cancer. Daniel G. Miller Lecture.
    Jordan VC
    Ann N Y Acad Sci; 2001 Dec; 952():60-72. PubMed ID: 11795444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiestrogens: clinical applications of pharmacology.
    Jordan VC
    J Soc Gynecol Investig; 2000; 7(1 Suppl):S47-8. PubMed ID: 10732329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen to raloxifene and beyond.
    O'Regan RM; Jordan VC
    Semin Oncol; 2001 Jun; 28(3):260-73. PubMed ID: 11402436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.